GT201700179A - Formulaciones en polvo nasal para el tratamiento de hipoglicemia - Google Patents

Formulaciones en polvo nasal para el tratamiento de hipoglicemia

Info

Publication number
GT201700179A
GT201700179A GT201700179A GT201700179A GT201700179A GT 201700179 A GT201700179 A GT 201700179A GT 201700179 A GT201700179 A GT 201700179A GT 201700179 A GT201700179 A GT 201700179A GT 201700179 A GT201700179 A GT 201700179A
Authority
GT
Guatemala
Prior art keywords
powder formulations
treatment
hypoglycemia
nasal powder
hypoglycemia treatment
Prior art date
Application number
GT201700179A
Other languages
English (en)
Inventor
Sankaram B Mantripragada
Claude A Piche
Betsbrugge Jo Jan Filip Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201700179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT201700179A publication Critical patent/GT201700179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN EN POLVO QUE CONTIENE GLUCAGÓN O UN ANÁLOGO DE GLUCAGÓN PARA ADMINISTRACIÓN NASAL, ÚTIL EN EL TRATAMIENTO DE HIPOGLICEMIA, Y EN PARTICULAR EL TRATAMIENTO DE HIPOGLICEMIA SEVERA. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA UN MÉTODO PARA ELABORAR ESTA FORMULACIÓN EN POLVO, Y A DISPOSITIVOS Y MÉTODOS PARA USAR LA FORMULACIÓN EN POLVO.
GT201700179A 2015-02-17 2017-08-16 Formulaciones en polvo nasal para el tratamiento de hipoglicemia GT201700179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562117031P 2015-02-17 2015-02-17

Publications (1)

Publication Number Publication Date
GT201700179A true GT201700179A (es) 2018-11-23

Family

ID=55538593

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700179A GT201700179A (es) 2015-02-17 2017-08-16 Formulaciones en polvo nasal para el tratamiento de hipoglicemia

Country Status (41)

Country Link
US (3) US10213487B2 (es)
EP (3) EP3258919B2 (es)
JP (3) JP6522144B2 (es)
KR (1) KR102121443B1 (es)
CN (1) CN107278154B (es)
AU (2) AU2016220235B2 (es)
BR (1) BR112017014994B1 (es)
CA (1) CA2975562C (es)
CL (1) CL2017002031A1 (es)
CO (1) CO2017008148A2 (es)
CR (1) CR20170373A (es)
CY (1) CY1122716T1 (es)
DK (1) DK3258919T4 (es)
DO (1) DOP2017000179A (es)
EA (1) EA034820B1 (es)
EC (1) ECSP17053843A (es)
ES (1) ES2775498T5 (es)
FI (1) FI3258919T4 (es)
GT (1) GT201700179A (es)
HR (1) HRP20200222T4 (es)
HU (1) HUE049413T2 (es)
IL (1) IL253273B (es)
LT (1) LT3258919T (es)
MA (3) MA52253A (es)
MD (1) MD3258919T3 (es)
MX (1) MX2017010572A (es)
MY (1) MY175669A (es)
NZ (1) NZ734035A (es)
PE (1) PE20171334A1 (es)
PH (1) PH12017501486A1 (es)
PL (1) PL3258919T5 (es)
PT (1) PT3258919T (es)
RS (1) RS59918B2 (es)
SA (1) SA517382068B1 (es)
SG (1) SG11201705640PA (es)
SI (1) SI3258919T2 (es)
SV (1) SV2017005515A (es)
TN (1) TN2017000349A1 (es)
UA (1) UA121874C2 (es)
WO (1) WO2016133863A1 (es)
ZA (2) ZA201704944B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175669A (en) * 2015-02-17 2020-07-03 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CA3071552A1 (en) 2017-08-20 2019-02-28 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
EP3684180A4 (en) * 2017-09-21 2021-07-07 The Scripps Research Institute NEW THERAPIES FOR THE TREATMENT AND PREVENTION OF CHRONIC RHINOSINUSITIS
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
AR121581A1 (es) 2020-03-16 2022-06-15 Zealand Pharma As Formulaciones líquidas de análogos de glucagón
KR20230012502A (ko) 2020-05-18 2023-01-26 오렉쏘 에이비 약물 전달을 위한 신규한 약학 조성물
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US6398074B1 (en) 1998-03-10 2002-06-04 Valois S.A. Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir
JP4072319B2 (ja) 1998-03-13 2008-04-09 ノヴォ ノルディスク アクティーゼルスカブ 安定化水溶性ペプチド溶液
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
US7722566B2 (en) 2003-10-09 2010-05-25 Shin Nippon Biomedical Laboratories, Ltd. Device to deliver a powdery medicine into nasal cavity
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
JP2009518315A (ja) * 2005-12-02 2009-05-07 エムディーアールエヌエー，インコーポレイテッド グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
CN102292348B (zh) 2008-12-15 2015-07-08 西兰制药公司 胰高血糖素类似物
KR20110126589A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
AP2013006671A0 (en) 2010-06-24 2013-01-31 Zealand Pharma As Glucagon analogues
AP2014007797A0 (en) 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
EP3248642B1 (en) 2012-06-28 2020-04-08 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
MY175669A (en) * 2015-02-17 2020-07-03 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia

Also Published As

Publication number Publication date
SG11201705640PA (en) 2017-08-30
RS59918B1 (sr) 2020-03-31
CA2975562A1 (en) 2016-08-25
MA41547B1 (fr) 2020-04-30
MA52253A (fr) 2021-02-17
EP3673900A1 (en) 2020-07-01
KR20170103934A (ko) 2017-09-13
TN2017000349A1 (en) 2019-01-16
AU2016220235B2 (en) 2021-04-29
KR102121443B1 (ko) 2020-06-10
WO2016133863A1 (en) 2016-08-25
CR20170373A (es) 2017-09-18
IL253273A0 (en) 2017-08-31
US10213487B2 (en) 2019-02-26
EP3258919B1 (en) 2020-01-15
SI3258919T1 (sl) 2020-03-31
BR112017014994B1 (pt) 2023-12-19
JP6522144B2 (ja) 2019-05-29
HRP20200222T4 (hr) 2022-12-23
ZA201704944B (en) 2021-05-26
CN107278154A (zh) 2017-10-20
JP7094242B2 (ja) 2022-07-01
JP2021107418A (ja) 2021-07-29
NZ734035A (en) 2019-06-28
JP2019147817A (ja) 2019-09-05
ES2775498T5 (es) 2023-01-31
HUE049413T2 (hu) 2020-09-28
JP7362687B2 (ja) 2023-10-17
SA517382068B1 (ar) 2020-10-26
PE20171334A1 (es) 2017-09-13
AU2016220235A1 (en) 2017-07-20
US20190282666A1 (en) 2019-09-19
EA201791560A1 (ru) 2018-02-28
MX2017010572A (es) 2017-12-07
CA2975562C (en) 2020-04-28
ECSP17053843A (es) 2017-11-30
MD3258919T2 (ro) 2020-07-31
AU2021203035A1 (en) 2021-06-10
PL3258919T5 (pl) 2023-02-27
SI3258919T2 (sl) 2023-01-31
BR112017014994A2 (pt) 2018-03-20
CY1122716T1 (el) 2021-03-12
EA034820B1 (ru) 2020-03-25
PT3258919T (pt) 2020-03-26
CL2017002031A1 (es) 2018-03-23
MD3258919T3 (ro) 2023-04-30
EP3258919B2 (en) 2022-11-09
JP2018507852A (ja) 2018-03-22
EP3258919A1 (en) 2017-12-27
MY175669A (en) 2020-07-03
HRP20200222T1 (hr) 2020-05-29
SV2017005515A (es) 2018-08-27
LT3258919T (lt) 2020-02-25
US20230302093A1 (en) 2023-09-28
DOP2017000179A (es) 2017-08-31
ES2775498T3 (es) 2020-07-27
ZA201901241B (en) 2020-10-28
EP3673899A1 (en) 2020-07-01
CO2017008148A2 (es) 2017-11-30
RS59918B2 (sr) 2023-01-31
AU2021203035B2 (en) 2023-07-13
DK3258919T4 (da) 2022-11-21
IL253273B (en) 2019-08-29
CN107278154B (zh) 2021-04-09
FI3258919T4 (fi) 2023-02-09
MA52252A (fr) 2021-02-17
UA121874C2 (uk) 2020-08-10
US20180000904A1 (en) 2018-01-04
PL3258919T3 (pl) 2020-08-10
PH12017501486A1 (en) 2018-01-15
DK3258919T3 (da) 2020-03-23

Similar Documents

Publication Publication Date Title
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2016002971A1 (es) Combinación.
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EP3808367A3 (en) Targeting aneurysm disease by modulating phagocytosis pathways
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
CL2016003271A1 (es) Métodos para tratar infecciones
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита